Taken together, these data suggest that the biology relevant to ibrutinib activity in FL may extend beyond the BTK‐NF‐κB pathway, to epigenetic changes in the expression of key tumor‐related genes, gene and protein regulation, DNA repair, cell cycle progression, and other cellular processes. The gene discussed is NFKB1; the disease is neoplasm.